{"id":"W2570114477","doi":"10.1016/j.jtho.2016.11.1785","title":"P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; T790M; non-small cell lung cancer (NSCLC); Internal medicine; Oncology; Osimertinib; Lung cancer; Erlotinib; EGFR inhibitors; Acquired resistance; Phases of clinical research; Resistance mutation; Cancer; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Gefitinib; Clinical trial; A549 cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001766176,0.001678374,0.002865675,0.0004747052,0.0004803718,0.001645338,0.001230587,0.00136277,0.004178183],"category_scores_gemma":[0.0008936228,0.0006536065,0.002563865,0.0006279013,0.0009305931,0.001121489,0.000436723,0.004047985,0.00125319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001348642,"about_ca_system_score_gemma":0.001980913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002538023,"about_ca_topic_score_gemma":0.007009399,"domain_scores_codex":[0.9994856,0.0002161614,0.00002791113,0.00007703504,0.00005488487,0.0001384019],"domain_scores_gemma":[0.9992962,0.0001050255,0.00009373239,0.00005247321,0.00005139497,0.0004012067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7516063,0.03242593,0.009101217,0.001460674,0.004537344,0.0004226618,0.0002846493,0.003855155,0.03730198,0.0005330354,0.01128107,0.1471899],"study_design_scores_gemma":[0.689456,0.2743674,0.02154104,0.00008236391,0.002533165,0.000549965,0.0001257996,0.001265323,0.003996882,0.0003140002,0.005707152,0.00006093264],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820618,0.005940182,0.0005056008,0.001304349,0.0002656651,0.001630154,0.00403353,0.0001686927,0.00409016],"genre_scores_gemma":[0.975248,0.005049434,0.001247182,0.001809336,0.0002996284,0.001431461,0.01084143,0.0001095291,0.003964095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004178183,"threshold_uncertainty_score":0.01397747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240743886775497,"score_gpt":0.4393268700468884,"score_spread":0.4169194311791334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}